Gilead Sciences (GILD) 106.53 $GILD
Final Glance: Biotechnology companies
AP - Mon Sep 08, 5:38PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:05PM CDT
The FDA has approved Keryx's (KERX) ferric citrate to control serum phosphorus levels in patients suffering from CKD on dialysis.
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.
Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 2:39PM CDT
Gilead (GILD) is in talks with generic players on Sovaldi.
Midday Glance: Biotechnology companies
AP - Mon Sep 08, 1:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Early Glance: Biotechnology companies
AP - Mon Sep 08, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:39AM CDT
ZIOPHARM Oncology, Inc. (ZIOP) was a big mover last session, as its shares rose over 10% on the day.
Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:55AM CDT
Keryx Biopharmaceuticals has been witnessing a negative trend in its earnings estimate front and possess an unfavorable Zacks Rank #4 (Sell)
BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:51AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as its shares rose almost 9% on the day.
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
Business Wire - Mon Sep 08, 7:45AM CDT
-- Data Presented at the ERS International Congress 2014 --
Is a Cheap Hepatitis C Cure About to Go Global?
Todd Campbell, The Motley Fool - Motley Fool - Sun Sep 07, 2:03PM CDT
Source: Gilead Sciences Last December, the FDA ushered in a new era in hepatitis C treatment when it approved Gilead Sciences ' Sovaldi -- a nucleotide analog NS5B polymerase inhibitor that simply knocks-out hepatitis C cold. In trials, 90% of...
Meet 5 IBD 50 Stocks Expanding Into New Markets
at Investor's Business Daily - Sat Sep 06, 7:01AM CDT
The IBD 50 list ranks stocks on a combination of recent profit growth and key measures such as return on equity, sales growth and profit margins, listing the strongest stocks first. Today's IBD 50 includes five companies that are expanding into new...
'Fast Money' Recap: Stocks Climb, Bonds Fall This Week
at The Street - Sat Sep 06, 4:00AM CDT
The trading panel discussed the overall market and whether to trade Chinese stocks.
Final Glance: Biotechnology companies
AP - Mon Sep 08, 5:38PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:05PM CDT
The FDA has approved Keryx's (KERX) ferric citrate to control serum phosphorus levels in patients suffering from CKD on dialysis.
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 5:00PM CDT
OncoMed Pharmaceuticals' (OMED) shares were up 5.7% with the FDA lifting the partial clinical hold on ipafricept for ovarian cancer, pancreatic cancer and liver cancer.
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:35PM CDT
The FDA has granted orphan drug designation to Prana Biotechnology's Huntington disease candidate, PBT2.
Novartis (NVS) Presents Positive Data on Ultibro Breezhaler - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:05PM CDT
Novartis (NVS) presented encouraging data on Ultibro Breezhaler from the LANTERN study at the European Respiratory Society (ERS) International Congress in Germany.
Bayer/Regeneron Looking for Eylea Label Expansion in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:45PM CDT
Bayer submitted an MAA for Eylea in Japan for the treatment of patients suffering from macular edema secondary to BRVO.
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 3:30PM CDT
Bristol-Myers (BMY) filed a patent infringement case against Merck (MRK).
Gilead Down on Likely Sovaldi Generic Deal in Poor Nations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 2:39PM CDT
Gilead (GILD) is in talks with generic players on Sovaldi.
Midday Glance: Biotechnology companies
AP - Mon Sep 08, 1:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Early Glance: Biotechnology companies
AP - Mon Sep 08, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
ZIOPHARM Oncology (ZIOP) in Focus: Stock Rises 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:39AM CDT
ZIOPHARM Oncology, Inc. (ZIOP) was a big mover last session, as its shares rose over 10% on the day.
Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:55AM CDT
Keryx Biopharmaceuticals has been witnessing a negative trend in its earnings estimate front and possess an unfavorable Zacks Rank #4 (Sell)
BioDelivery Sciences (BDSI) Jumps: Stock Rises 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:51AM CDT
BioDelivery Sciences International, Inc. (BDSI) was a big mover last session, as its shares rose almost 9% on the day.
J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig
at The Street - Mon Sep 08, 7:48AM CDT
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
Business Wire - Mon Sep 08, 7:45AM CDT
-- Data Presented at the ERS International Congress 2014 --
Is a Cheap Hepatitis C Cure About to Go Global?
Todd Campbell, The Motley Fool - Motley Fool - Sun Sep 07, 2:03PM CDT
Source: Gilead Sciences Last December, the FDA ushered in a new era in hepatitis C treatment when it approved Gilead Sciences ' Sovaldi -- a nucleotide analog NS5B polymerase inhibitor that simply knocks-out hepatitis C cold. In trials, 90% of...
Meet 5 IBD 50 Stocks Expanding Into New Markets
at Investor's Business Daily - Sat Sep 06, 7:01AM CDT
The IBD 50 list ranks stocks on a combination of recent profit growth and key measures such as return on equity, sales growth and profit margins, listing the strongest stocks first. Today's IBD 50 includes five companies that are expanding into new...
'Fast Money' Recap: Stocks Climb, Bonds Fall This Week
at The Street - Sat Sep 06, 4:00AM CDT
The trading panel discussed the overall market and whether to trade Chinese stocks.
